{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T17:23:44Z","timestamp":1793381024495,"version":"4.5.0"},"reference-count":197,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T00:00:00Z","timestamp":1720396800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020955","name":"GlaxoSmithKline Biologicals SA","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100020955","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Human Vaccines &amp; Immunotherapeutics"],"published-print":{"date-parts":[[2024,12,31]]},"DOI":"10.1080\/21645515.2024.2357924","type":"journal-article","created":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T18:35:10Z","timestamp":1720463710000},"update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":40,"title":["4CMenB journey to the 10-year anniversary and beyond"],"prefix":"10.1080","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0369-7715","authenticated-orcid":false,"given":"V\u00e9ronique","family":"Abitbol","sequence":"first","affiliation":[{"name":"GSK","place":["Rueil-Malmaison, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9023-581X","authenticated-orcid":false,"given":"Federico","family":"Martin\u00f3n-Torres","sequence":"additional","affiliation":[{"name":"Instituto de Investigaci\u00f3n Sanitaria de Santiago and Universidad de","place":["Santiago de Compostela, Spain"]},{"name":"Hospital Cl\u00ednico Universitario de Santiago","place":["Santiago de Compostela, Spain"]},{"name":"Instituto de Salud Carlos III","place":["Madrid, Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0716-3174","authenticated-orcid":false,"given":"Muhamed-Kheir","family":"Taha","sequence":"additional","affiliation":[{"name":"National Reference Center for Meningococci and Haemophilus influenzae","place":["Paris, France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6018-3863","authenticated-orcid":false,"given":"Terry","family":"Nolan","sequence":"additional","affiliation":[{"name":"Peter Doherty Institute for Infection & Immunity at University of Melbourne and Murdoch Children\u2019s Research Institute","place":["Melbourne, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8635-6424","authenticated-orcid":false,"given":"Alessandro","family":"Muzzi","sequence":"additional","affiliation":[{"name":"GSK","place":["Siena, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4115-9442","authenticated-orcid":false,"given":"Stefania","family":"Bambini","sequence":"additional","affiliation":[{"name":"GSK","place":["Siena, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0691-6568","authenticated-orcid":false,"given":"Ray","family":"Borrow","sequence":"additional","affiliation":[{"name":"UK Health Security Agency","place":["Manchester, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7661-4370","authenticated-orcid":false,"given":"Daniela","family":"Toneatto","sequence":"additional","affiliation":[{"name":"GSK","place":["Siena, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8618-9726","authenticated-orcid":false,"given":"Laura","family":"Serino","sequence":"additional","affiliation":[{"name":"GSK","place":["Siena, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8827-254X","authenticated-orcid":false,"given":"Rino","family":"Rappuoli","sequence":"additional","affiliation":[{"name":"GSK","place":["Siena, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7800-1404","authenticated-orcid":false,"given":"Mariagrazia","family":"Pizza","sequence":"additional","affiliation":[{"name":"GSK","place":["Siena, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2024,7,8]]},"reference":[{"key":"e_1_3_6_2_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-022-13342-2"},{"key":"e_1_3_6_3_1","doi-asserted-by":"publisher","DOI":"10.1080\/23744235.2021.1971289"},{"key":"e_1_3_6_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2020.05.079"},{"key":"e_1_3_6_5_1","unstructured":"U.S. Food & Drug Administration. PENBRAYA. 2023 [accessed 2024 Mar 15]. https:\/\/www.fda.gov\/vaccines-blood-biologics\/vaccines\/penbraya."},{"key":"e_1_3_6_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2022.09.001"},{"key":"e_1_3_6_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2214924"},{"key":"e_1_3_6_8_1","doi-asserted-by":"publisher","DOI":"10.1128\/cvi.00566-16"},{"key":"e_1_3_6_9_1","doi-asserted-by":"publisher","DOI":"10.4161\/hv.24129"},{"key":"e_1_3_6_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/nri3694"},{"key":"e_1_3_6_11_1","unstructured":"GSK. Bexsero prescribing information (U.S.A). 2022 [accessed 2024 Mar 15]. https:\/\/gskpro.com\/content\/dam\/global\/hcpportal\/en_US\/Prescribing_Information\/Bexsero\/pdf\/BEXSERO.PDF."},{"key":"e_1_3_6_12_1","unstructured":"European Medicines Agency. Annex 1. Summary of product characteristics (Bexsero). 2020 [accessed 2024 Mar 15]. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/bexsero-epar-product-information_en.pdf."},{"key":"e_1_3_6_13_1","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2018.1483726"},{"key":"e_1_3_6_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2012.01.033"},{"key":"e_1_3_6_15_1","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2018.1547637"},{"key":"e_1_3_6_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2020.07.025"},{"key":"e_1_3_6_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2022.10.022"},{"key":"e_1_3_6_18_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-021-06781-6"},{"key":"e_1_3_6_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2006.03.091"},{"key":"e_1_3_6_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-013-0155-7"},{"key":"e_1_3_6_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2017.12.005"},{"key":"e_1_3_6_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2017.05.023"},{"key":"e_1_3_6_23_1","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2018.1537756"},{"key":"e_1_3_6_24_1","unstructured":"Govern d\u2019Andorra. Recomanacions sobre l\u2019administraci\u00f3 de la vacunaci\u00f3 enfront del meningococ B (Bexsero). 2016 [accessed 2024 Mar 15]. https:\/\/www.salut.ad\/images\/stories\/Salut\/pdfs\/temes_salut\/Recomanacions_Vacuna_Bexero.pdf."},{"key":"e_1_3_6_25_1","unstructured":"Chile Ministerio de Salud. National immunization program. 2024 [accessed 2024 Mar 15]. https:\/\/www.minsal.cl\/programa-nacional-de-inmunizaciones\/."},{"key":"e_1_3_6_26_1","unstructured":"European Centre for Disease Prevention and Control. Czechia: recommended vaccinations. 2024 [accessed 2024 Mar 15]. https:\/\/vaccine-schedule.ecdc.europa.eu\/Scheduler\/ByCountry?SelectedCountryId=201&IncludeChildAgeGroup=true&IncludeChildAgeGroup=false&IncludeAdultAgeGroup=true&IncludeAdultAgeGroup=false."},{"key":"e_1_3_6_27_1","unstructured":"MUDr Jarom\u00edr Vom\u00e1\u010dka. Vaccination against infectious diseases in the Czech Republic. 2023 [accessed 2024 Mar 15]. http:\/\/www.mudrvomacka.cz\/index.php?option=com_content&amp;view=article&amp;id=8&amp;Itemid=152&amp;lang=en."},{"key":"e_1_3_6_28_1","unstructured":"Minist\u00e8re de la Sant\u00e9 et de la Pr\u00e9vention. Le calendrier des vaccinations. 2023 [accessed 2024 Mar 15]. https:\/\/sante.gouv.fr\/prevention-en-sante\/preserver-sa-sante\/vaccination\/calendrier-vaccinal."},{"key":"e_1_3_6_29_1","unstructured":"Health Service Executive (Ireland). Immunisation schedule 2023. 2023 [accessed 2024 Mar 15]. https:\/\/www.hse.ie\/eng\/health\/immunisation\/pubinfo\/currentschedule.html."},{"key":"e_1_3_6_30_1","unstructured":"Ministero della Salute (Italy). Piano Nazionale Prevenzione Vaccinale PNPV 2023\u20132025. 2023 [accessed 2024 Mar 15]. https:\/\/www.quotidianosanita.it\/allegati\/allegato1679488094.pdf."},{"key":"e_1_3_6_31_1","unstructured":"Ministry of Health for the Republic of Lithuania. Recommendation for revised vaccination against meningococcal type B infection. 2018 [accessed 2024 Mar 15]. https:\/\/nvsc.lrv.lt\/uploads\/nvsc\/documents\/files\/Rekomendacijos%20skiepijant%20nuo%20B%20tipo%20MI(2).pdf."},{"key":"e_1_3_6_32_1","unstructured":"Ministry of Health for the Republic of Lithuania. m. Bir\u017eelio 12 d. \u012esakymo nr. V-757 \u201cd\u0117l lietuvos respublikos vaik\u0173 profilaktini\u0173 skiepijim\u0173 kalendoriaus patvirtinimo\u201cpakeitimo. 2018 [accessed 2024 Mar 15]. https:\/\/e-seimas.lrs.lt\/portal\/legalAct\/lt\/TAD\/f4a925d0f50f11e79a1bc86190c2f01a."},{"key":"e_1_3_6_33_1","unstructured":"Ministry for Health (Malta). National immunisation schedule. 2023 [accessed 2024 Mar 15]. https:\/\/healthservices.gov.mt\/en\/phc\/pchyhi\/Pages\/National-Immunisation-Schedule.aspx."},{"key":"e_1_3_6_34_1","unstructured":"Health New Zealand \u2013 Te Whatu Ora. New Zealand immunisation schedule. 2023 [accessed 2024 Mar 15]. https:\/\/www.tewhatuora.govt.nz\/for-the-health-sector\/vaccine-information\/new-zealand-immunisation-schedule\/."},{"key":"e_1_3_6_35_1","unstructured":"Gabinete do Secret\u00e1rio de Estado da Sa\u00fade (Portugal). Aprova o novo esquema vacinal do Programa Nacional de Vacina\u00e7\u00e3o (PNV) revo-gando com exce\u00e7\u00e3o do seu n.\u00ba 6 o Despacho n.\u00ba 10441\/2016 de 9 de agosto. 2019 [accessed 2024 Mar 15]. https:\/\/files.dre.pt\/2s\/2019\/12\/250000000\/0003000031.pdf."},{"key":"e_1_3_6_36_1","unstructured":"SIP-SPP Vaccine Commission (Portugal). Recommendations on vaccines outside the national vaccination program. 2020 [accessed 2024 Mar 15]. https:\/\/www.spp.pt\/UserFiles\/file\/Seccao_Infecciologia\/recomendacoes%20vacinas_sip_final_28set_2.pdf."},{"key":"e_1_3_6_37_1","unstructured":"Istituto per la Sicurezza Sociale (San Marino). Recommended vaccinations. 2023 [accessed 2024 Mar 15]. https:\/\/www.iss.sm\/on-line\/home\/vaccini-e-vaccinazioni\/vaccinazioni-raccomandate.html."},{"key":"e_1_3_6_38_1","unstructured":"Asociaci\u00f3n Espa\u00f1ola de Pediatr\u00eda. Vacuna meningococo B. 2023 [accessed 2024 Mar 15]. https:\/\/vacunasaep.org\/familias\/vacunas-una-a-una\/vacuna-meningococo-b."},{"key":"e_1_3_6_39_1","unstructured":"Consejo Interterritorial del Sistema Nacional de Salud. Calendario com\u00fan de vacunaci\u00f3n a lo largo de toda la vida. Calendario recomendado a\u00f1o 2024. 2024 [accessed 2024 Mar 15]. https:\/\/www.sanidad.gob.es\/areas\/promocionPrevencion\/vacunaciones\/calendario\/docs\/CalendarioVacunacion_Todalavida.pdf."},{"key":"e_1_3_6_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2015.09.035"},{"key":"e_1_3_6_41_1","unstructured":"UK Health Security Agency. The routine immunisation schedule. 2023 [accessed 2024 Mar 15]. https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/1055877\/UKHSA-12155-routine-complete-immunisation-schedule_Feb2022.pdf."},{"key":"e_1_3_6_42_1","unstructured":"Epidemiologisches Bulletin. STIKO: Standardimpfung von S\u00e4uglingen gegen Meningokokken der Serogruppe B. 2024 [accessed 2024 Mar 15]. https:\/\/www.rki.de\/DE\/Content\/Infekt\/EpidBull\/Archiv\/2024\/Ausgaben\/03_24.pdf?__blob=publicationFile."},{"key":"e_1_3_6_43_1","unstructured":"Higher Council of Infectious Diseases. M\u00e9ningite et infections invasives \u00e0 m\u00e9ningocoques. 2023 [accessed 2024 Mar 15]. https:\/\/sante.public.lu\/fr\/espace-professionnel\/recommandations\/conseil-maladies-infectieuses\/meningite.html."},{"key":"e_1_3_6_44_1","unstructured":"Office f\u00e9d\u00e9ral de la sant\u00e9 publique OFSP. Plan de vaccination suisse. 2024 [accessed 2024 Mar 15]. https:\/\/www.bag.admin.ch\/bag\/fr\/home\/gesund-leben\/gesundheitsfoerderung-und-praevention\/impfungen-prophylaxe\/schweizerischer-impfplan.html."},{"key":"e_1_3_6_45_1","unstructured":"Haute Autorit\u00e9 de Sant\u00e9. Strat\u00e9gie de vaccination contre les infections invasives \u00e0 m\u00e9ningocoques. R\u00e9vision de la strat\u00e9gie contre les s\u00e9rogroupes ACWY et B. 2024 [accessed 2024 Mar 15]. https:\/\/www.has-sante.fr\/upload\/docs\/application\/pdf\/2024-03\/eco_sp_424_recovac_meningo.pdf#page=8."},{"key":"e_1_3_6_46_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.rr6909a1"},{"key":"e_1_3_6_47_1","unstructured":"Centers for Disease Control and Prevention. Meningococcal vaccine recommendations. 2023 [accessed 2024 Mar 15]. https:\/\/www.cdc.gov\/vaccines\/vpd\/mening\/hcp\/recommendations.html."},{"key":"e_1_3_6_48_1","doi-asserted-by":"publisher","DOI":"10.5694\/mja2.50481"},{"key":"e_1_3_6_49_1","unstructured":"Government of South Australia. Meningococcal B immunisation program. 2023 [accessed 2024 Mar 15]. https:\/\/www.sahealth.sa.gov.au\/wps\/wcm\/connect\/public+content\/sa+health+internet\/conditions\/immunisation\/immunisation+programs\/meningococcal+b+immunisation+program."},{"key":"e_1_3_6_50_1","unstructured":"Queensland Government. Immunisation schedule Queensland. 2024 [accessed 2024 Mar 15]. https:\/\/www.health.qld.gov.au\/clinical-practice\/guidelines-procedures\/diseases-infection\/immunisation\/schedule."},{"key":"e_1_3_6_51_1","unstructured":"Provincial government of Prince Edward Island. Free meningitis vaccine available to post-secondary students living in residence. 2023 [accessed 2024 Mar 15]. https:\/\/www.princeedwardisland.ca\/en\/news\/free-meningitis-vaccine-available-to-post-secondary-students-living-in-residence."},{"key":"e_1_3_6_52_1","unstructured":"Provincial government of Nova Scotia. More Nova Scotians eligible for meningococcal B vaccine. 2023 [accessed 2024 Mar 15]. https:\/\/novascotia.ca\/news\/release\/?id=20230525003."},{"key":"e_1_3_6_53_1","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2023.2245705"},{"key":"e_1_3_6_54_1","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2022.2021881"},{"key":"e_1_3_6_55_1","unstructured":"Immunisation Advisory Centre (New Zealand). MenB Bexsero quick facts. 2023 [accessed 2024 Mar 15]. https:\/\/www.immune.org.nz\/factsheets\/menb-bexsero."},{"key":"e_1_3_6_56_1","unstructured":"\u010cesk\u00e9 vakcinologick\u00e9 spole\u010dnosti \u010cLS JEP (Czechia). Doporu\u010den\u00ed \u010cesk\u00e9 vakcinologick\u00e9 spole\u010dnosti \u010cLS JEP pro o\u010dkov\u00e1n\u00ed proti invazivn\u00edm meningokokov\u00fdm onemocn\u011bn\u00edm. 2023 [accessed 2024 Mar 15]. https:\/\/www.vakcinace.eu\/storage\/files\/3\/doporuceni_a_stanoviska\/2023\/doporuceniockovaniprotiimofinal_6_3_2023.pdf."},{"key":"e_1_3_6_57_1","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2023.2186111"},{"key":"e_1_3_6_58_1","unstructured":"Region of Puglia. Calendario vaccinale per la vita della regione Puglia - ed. 2021. 2021 [accessed 2024 Mar 15]. https:\/\/www.sanita.puglia.it\/documents\/20182\/285275922\/DGR+1589_2021+Nuovo+calendario+vaccinale+ed.2021.pdf\/186500a3-134e-4dae-9d5c-c6e139280bcd."},{"key":"e_1_3_6_59_1","unstructured":"Region of Calabria. DCA 43\/2015 Calendario vaccinale regionale. 2022 [accessed 2024 Mar 15]. https:\/\/www.regione.calabria.it\/website\/portaltemplates\/view\/view_provvedimenti.cfm?63132."},{"key":"e_1_3_6_60_1","unstructured":"Region of Sicilia. Il calendario vaccinale della Regione Sicilia. 2017 [accessed 2024 Mar 15]. https:\/\/www.vaccinarsinsicilia.org\/vaccinazioni-sicilia\/calendario-vaccinale."},{"key":"e_1_3_6_61_1","unstructured":"Provincial government of Prince Edward Island. Meningococcal group A B C Y and W-135 vaccines. 2023 [accessed 2024 Mar 15]. https:\/\/www.princeedwardisland.ca\/en\/information\/health-and-wellness\/meningococcal-group-a-b-c-y-and-w-135-vaccines."},{"key":"e_1_3_6_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2015.05.027"},{"key":"e_1_3_6_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2018.10.096"},{"key":"e_1_3_6_64_1","doi-asserted-by":"publisher","DOI":"10.1128\/mSphere.00553-21"},{"key":"e_1_3_6_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2021.04.031"},{"key":"e_1_3_6_66_1","doi-asserted-by":"publisher","DOI":"10.1136\/archdischild-2019-318047"},{"key":"e_1_3_6_67_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2023.05.025"},{"key":"e_1_3_6_68_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1901229"},{"key":"e_1_3_6_69_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2021.11.015"},{"key":"e_1_3_6_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/s2352-4642(22)00379-0"},{"key":"e_1_3_6_71_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2019.06.021"},{"key":"e_1_3_6_72_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix154"},{"key":"e_1_3_6_73_1","doi-asserted-by":"publisher","DOI":"10.1177\/2051013616681365"},{"key":"e_1_3_6_74_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6520a3"},{"key":"e_1_3_6_75_1","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines8030469"},{"key":"e_1_3_6_76_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.29678"},{"key":"e_1_3_6_77_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.20449"},{"key":"e_1_3_6_78_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206433"},{"key":"e_1_3_6_79_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa1636"},{"key":"e_1_3_6_80_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1900236"},{"key":"e_1_3_6_81_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1473-3099(21)00754-4"},{"key":"e_1_3_6_82_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2023.05.021"},{"key":"e_1_3_6_83_1","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2023.2222015"},{"key":"e_1_3_6_84_1","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2021.2020043"},{"key":"e_1_3_6_85_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2012.85"},{"key":"e_1_3_6_86_1","doi-asserted-by":"publisher","DOI":"10.4161\/hv.28666"},{"key":"e_1_3_6_87_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(12)61961-8"},{"key":"e_1_3_6_88_1","doi-asserted-by":"publisher","DOI":"10.1136\/archdischild-2017-313419"},{"key":"e_1_3_6_89_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2018.10.095"},{"key":"e_1_3_6_90_1","doi-asserted-by":"publisher","DOI":"10.1097\/inf.0000000000002507"},{"key":"e_1_3_6_91_1","doi-asserted-by":"publisher","DOI":"10.1016\/s2352-4642(18)30103-2"},{"key":"e_1_3_6_92_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2021.02.065"},{"key":"e_1_3_6_93_1","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.es.2018.23.17.17-00468"},{"key":"e_1_3_6_94_1","unstructured":"Agenzia Italiana del Farmaco. Rapporto vaccini 2017. 2018 [accessed 2024 Mar 15]. https:\/\/www.aifa.gov.it\/sites\/default\/files\/Rapp_Vaccini_2017_0.pdf."},{"key":"e_1_3_6_95_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2020.07.009"},{"key":"e_1_3_6_96_1","unstructured":"Australian Government Therapeutic Goods Administration. Bexsero meningococcal B vaccine. Final update - monitoring finds no new or unexpected safety issues. 2016 [accessed 2024 Mar 15]. https:\/\/www.tga.gov.au\/news\/safety-alerts\/bexsero-meningococcal-b-vaccine."},{"key":"e_1_3_6_97_1","doi-asserted-by":"publisher","DOI":"10.33321\/cdi.2022.46.47"},{"key":"e_1_3_6_98_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2015.11.057"},{"key":"e_1_3_6_99_1","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.es.2018.23.28.1700590"},{"key":"e_1_3_6_100_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2019.07.017"},{"key":"e_1_3_6_101_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2020.05.055"},{"key":"e_1_3_6_102_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2020.05.089"},{"key":"e_1_3_6_103_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-021-00388-3"},{"key":"e_1_3_6_104_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2020.09.050"},{"key":"e_1_3_6_105_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-020-00370-x"},{"key":"e_1_3_6_106_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2012.12.022"},{"key":"e_1_3_6_107_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa1244"},{"key":"e_1_3_6_108_1","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines8020219"},{"key":"e_1_3_6_109_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy1061"},{"key":"e_1_3_6_110_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(17)31449-6"},{"key":"e_1_3_6_111_1","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines7010005"},{"key":"e_1_3_6_112_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.23487"},{"key":"e_1_3_6_113_1","doi-asserted-by":"publisher","DOI":"10.1016\/s2666-5247(22)00303-2"},{"key":"e_1_3_6_114_1","unstructured":"ClinicalTrials.gov. Study to assess gonorrhoeae immune responses induced by a N. Meningitidis vaccine (4cmenB). 2021 [accessed 2024 Mar 15]. https:\/\/www.clinicaltrials.gov\/study\/NCT04094883?term=NCT04094883&rank=1."},{"key":"e_1_3_6_115_1","unstructured":"ClinicalTrials.gov. Efficacy of immunization with 4C-MenB in preventing experimental urethral infection with Neisseria gonorrhoeae. 2023 [accessed 2024 Mar 15]. https:\/\/www.clinicaltrials.gov\/study\/NCT05294588?term=NCT05294588&rank=1."},{"key":"e_1_3_6_116_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.31742"},{"key":"e_1_3_6_117_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac436"},{"key":"e_1_3_6_118_1","unstructured":"ClinicalTrials.gov. Mucosal immunity against Neisseria gonorrhoeae after 4CMenB vaccination. 2023 [accessed 2024 Mar 15]. https:\/\/www.clinicaltrials.gov\/study\/NCT04722003?term=NCT04722003&rank=1."},{"key":"e_1_3_6_119_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1473-3099(21)00812-4"},{"key":"e_1_3_6_120_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofx180.002"},{"key":"e_1_3_6_121_1","unstructured":"ClinicalTrials.gov. Safety and efficacy study of meningococcal group B vaccine rMenB+OMV NZ (Bexsero) to prevent gonococcal infection. 2024 [accessed 2024 Mar 15]. https:\/\/www.clinicaltrials.gov\/study\/NCT04350138?term=NCT04350138&rank=1."},{"key":"e_1_3_6_122_1","doi-asserted-by":"publisher","DOI":"10.1097\/olq.0000000000001771"},{"key":"e_1_3_6_123_1","unstructured":"ClinicalTrials.gov. Gonococcal vaccine study in key populations in Kenya (BexKPK). 2022 [accessed 2024 Mar 15]. https:\/\/www.clinicaltrials.gov\/study\/NCT04297436?term=NCT04297436&rank=1."},{"key":"e_1_3_6_124_1","unstructured":"ClinicalTrials.gov. Efficacy trial on meningococcal B vaccine for preventing gonorrhea infections. 2023 [accessed 2024 Mar 15]. https:\/\/www.clinicaltrials.gov\/study\/NCT05766904?term=NCT05766904&rank=1."},{"key":"e_1_3_6_125_1","unstructured":"ClinicalTrials.gov. Immunisation for adolescents against serious communicable diseases (B Part of it NT). 2023 [accessed 2024 Mar 15]. https:\/\/www.clinicaltrials.gov\/study\/NCT04398849?term=NCT04398849&rank=1."},{"key":"e_1_3_6_126_1","unstructured":"ClinicalTrials.gov. Efficacy study of 4CMenB (Bexsero\u00ae) to prevent gonorrhoea infection in gay and bisexual men (GoGovax). 2023 [accessed 2024 Mar 15]. https:\/\/www.clinicaltrials.gov\/study\/NCT04415424?term=NCT04415424&rank=1."},{"key":"e_1_3_6_127_1","unstructured":"Australian New Zealand Clinical Trials Registry. MenGO: Does the licensed meningococcal vaccine Bexsero\u00ae provide cross- protection against gonorrhoea in gay and bisexual men? 2023 [accessed 2024 Mar 15]. https:\/\/www.anzctr.org.au\/Trial\/Registration\/TrialReview.aspx?ACTRN=12619001478101."},{"key":"e_1_3_6_128_1","volume-title":"Conference on Retroviruses and Opportunistic Infections Abstract book (Abstract 124)","author":"Molina J-M","unstructured":"Molina J-M, Ber\u00e7ot B, Assoumou L, Algarte-Genin M, Rubenstein E, Pialoux G, Katlama C, Surgers L, Bebear C, Dupin N. et al. Final results of ANRS 174 DOXYVAC: A randomized trial to prevent STI in MSM on PrEP. Conference on Retroviruses and Opportunistic Infections Abstract book (Abstract 124); 2024 Mar 3-6; Denver, Colorado, USA https:\/\/www.croiconference.org\/abstract\/final-results-of-anrs-174-doxyvac-a-randomized-trial-to-prevent-sti-in-msm-on-prep\/."},{"key":"e_1_3_6_129_1","doi-asserted-by":"publisher","DOI":"10.1097\/olq.0000000000001793"},{"key":"e_1_3_6_130_1","volume-title":"Slides presented at Conference on Retroviruses and Opportunistic Infections","author":"Molina J-M","year":"2024","unstructured":"Molina J-M, Ber\u00e7ot B, Assoumou L, Algarte-Genin M, Rubenstein E, Pialoux G, Katlama C, Surgers L, Bebear C, Dupin N. et al. Final results of ANRS 174 DOXYVAC: A randomized trial to prevent STIs in MSM on PrEP. Slides presented at Conference on Retroviruses and Opportunistic Infections; 2024 Mar 3\u20136 [accessed 2024 Mar 15]; Denver, Colorado, USA. https:\/\/www.natap.org\/2024\/CROI\/croi_33.htm."},{"key":"e_1_3_6_131_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-022-14670-z"},{"key":"e_1_3_6_132_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2022.10.031"},{"key":"e_1_3_6_133_1","unstructured":"U.S. Department of Health and Human Services. Reduce gonorrhea rates in male adolescents and young men \u2014 STI\u201102. 2020 [accessed 2024 Mar 15]. https:\/\/health.gov\/healthypeople\/objectives-and-data\/browse-objectives\/sexually-transmitted-infections\/reduce-gonorrhea-rates-male-adolescents-and-young-men-sti-02."},{"key":"e_1_3_6_134_1","unstructured":"European Centre for Disease Prevention and Control. Invasive meningococcal disease. Annual epidemiological report for 2021. 2023 [accessed 2024 Mar 15]. https:\/\/www.ecdc.europa.eu\/sites\/default\/files\/documents\/MEN%20AER%202021.pdf."},{"key":"e_1_3_6_135_1","unstructured":"Centers for Disease Control and Prevention. Meningococcal disease Surveillance and Trends. 2024 [accessed 2024 Mar 15]. https:\/\/www.cdc.gov\/meningococcal\/php\/surveillance\/?CDC_AAref_Val=https:\/\/www.cdc.gov\/meningococcal\/surveillance\/index.html."},{"key":"e_1_3_6_136_1","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2019.1627159"},{"key":"e_1_3_6_137_1","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2019.1580579"},{"key":"e_1_3_6_138_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-022-12795-9"},{"key":"e_1_3_6_139_1","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2019.1557520"},{"key":"e_1_3_6_140_1","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2023.2245467"},{"key":"e_1_3_6_141_1","doi-asserted-by":"publisher","DOI":"10.1093\/jtm\/taz034"},{"key":"e_1_3_6_142_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6738a4"},{"key":"e_1_3_6_143_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix438"},{"key":"e_1_3_6_144_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-015-0538-6"},{"key":"e_1_3_6_145_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab917"},{"key":"e_1_3_6_146_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2020.11.068"},{"key":"e_1_3_6_147_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.8573"},{"key":"e_1_3_6_148_1","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2021.1923349"},{"key":"e_1_3_6_149_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2023.06.034"},{"key":"e_1_3_6_150_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2017-4250"},{"key":"e_1_3_6_151_1","doi-asserted-by":"publisher","DOI":"10.1111\/cei.13368"},{"key":"e_1_3_6_152_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2022.06.024"},{"key":"e_1_3_6_153_1","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.13495"},{"key":"e_1_3_6_154_1","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.13586"},{"key":"e_1_3_6_155_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eimc.2016.02.015"},{"key":"e_1_3_6_156_1","unstructured":"World Health Organization. Defeating meningitis by 2030: a global road map. 2021 [accessed 2024 Mar 15]. https:\/\/www.who.int\/publications\/i\/item\/9789240026407."},{"key":"e_1_3_6_157_1","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2022.2052048"},{"key":"e_1_3_6_158_1","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2020.1849518"},{"key":"e_1_3_6_159_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.idnow.2021.05.001"},{"key":"e_1_3_6_160_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2020.07.034"},{"key":"e_1_3_6_161_1","doi-asserted-by":"publisher","DOI":"10.1128\/microbiolspec.MDNA3-0015-2014"},{"key":"e_1_3_6_162_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-genet-120213-092007"},{"key":"e_1_3_6_163_1","doi-asserted-by":"publisher","DOI":"10.1128\/cvi.00202-12"},{"key":"e_1_3_6_164_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1013758107"},{"key":"e_1_3_6_165_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2018.12.061"},{"key":"e_1_3_6_166_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2015.04.015"},{"key":"e_1_3_6_167_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2180-14-111"},{"key":"e_1_3_6_168_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1473-3099(13)70006-9"},{"key":"e_1_3_6_169_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2015.11.070"},{"key":"e_1_3_6_170_1","doi-asserted-by":"publisher","DOI":"10.1128\/mSphere.00376-20"},{"issue":"2","key":"e_1_3_6_171_1","first-page":"103","article-title":"Predicted strain coverage of a new protein-based meningococcal vaccine in the Czech Republic","volume":"63","author":"K\u0159\u00ed\u017eov\u00e1 P","year":"2014","unstructured":"K\u0159\u00ed\u017eov\u00e1 P, Mus\u00edlek M, Vackov\u00e1 Z, Koz\u00e1kov\u00e1 J, Claus H, Vogel U, Medini D. Predicted strain coverage of a new protein-based meningococcal vaccine in the Czech Republic. Epidemiol Mikrobiol Imunol. 2014;63(2):103\u20136.","journal-title":"Epidemiol Mikrobiol Imunol"},{"key":"e_1_3_6_172_1","doi-asserted-by":"publisher","DOI":"10.1128\/mSphere.00883-19"},{"key":"e_1_3_6_173_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1473-3099(17)30170-6"},{"key":"e_1_3_6_174_1","doi-asserted-by":"publisher","DOI":"10.1128\/mSphere.00196-18"},{"key":"e_1_3_6_175_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0150721"},{"key":"e_1_3_6_176_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0176177"},{"key":"e_1_3_6_177_1","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2021.2004055"},{"key":"e_1_3_6_178_1","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2021.1904758"},{"key":"e_1_3_6_179_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2020.10.008"},{"key":"e_1_3_6_180_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2020.12.034"},{"key":"e_1_3_6_181_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2013.08.006"},{"key":"e_1_3_6_182_1","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2019.1688039"},{"key":"e_1_3_6_183_1","doi-asserted-by":"publisher","DOI":"10.1128\/cvi.00669-14"},{"key":"e_1_3_6_184_1","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2022.2050697"},{"key":"e_1_3_6_185_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-021-00286-8"},{"key":"e_1_3_6_186_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2018.07.016"},{"key":"e_1_3_6_187_1","doi-asserted-by":"publisher","DOI":"10.1128\/msphere.00385-22"},{"key":"e_1_3_6_188_1","unstructured":"EU Clinical Trials Register. Clinical trial results: A phase III randomized controlled observer-blind study to demonstrate effectiveness immunogenicity and safety of GSK\u2019s meningococcal Group B and combined ABCWY vaccines when administered to healthy adolescents and young adults. 2024 [accessed 2024 Mar 15]. https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2019-001666-15\/results."},{"key":"e_1_3_6_189_1","unstructured":"ClinicalTrials.gov. Effectiveness of GlaxoSmithKline Biologicals S.A\u2019s meningococcal group B and combined ABCWY vaccines in healthy adolescents and young adults. 2024 [accessed 2024 Mar 15]. https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT04502693."},{"key":"e_1_3_6_190_1","unstructured":"New York State Department Of Health AIDS Institute. Immunizations for adults with HIV. Meningococcal Serogroup B. 2023 [accessed 2024 Mar 15]. https:\/\/www.hivguidelines.org\/guideline\/hiv-immunizations\/?mytab=tab_10&mycollection=hiv-care."},{"key":"e_1_3_6_191_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.p2696"},{"key":"e_1_3_6_192_1","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2022.1000657"},{"key":"e_1_3_6_193_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-023-00778-1"},{"key":"e_1_3_6_194_1","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2023.2211163"},{"key":"e_1_3_6_195_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa1733"},{"key":"e_1_3_6_196_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiab444"},{"key":"e_1_3_6_197_1","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines10020309"},{"key":"e_1_3_6_198_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-037358"}],"container-title":["Human Vaccines &amp; Immunotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/21645515.2024.2357924","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T17:21:11Z","timestamp":1744651271000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/21645515.2024.2357924"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,8]]},"references-count":197,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,12,31]]}},"alternative-id":["10.1080\/21645515.2024.2357924"],"URL":"https:\/\/doi.org\/10.1080\/21645515.2024.2357924","relation":{},"ISSN":["2164-5515","2164-554X"],"issn-type":[{"value":"2164-5515","type":"print"},{"value":"2164-554X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,8]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=khvi20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=khvi20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-10-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-03","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-17","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"2357924"}}